Vpriv
Vpriv ingredients
| Active ingredient | Strength |
|---|---|
| Velaglucerase Alfa | 2.5 mg/mL |
What Vpriv is used for
The FDA lists the approved uses on the official label (below). In the EU, velaglucerase alfa is approved as Vpriv for:
Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Vpriv
- Generic name
- Velaglucerase alfa
- Made by
- Takeda Pharmaceuticals America, Inc.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- Drug class
- Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
- FDA approval
- Biologic licence (BLA) BLA022575
- On the US market since
- 2010
Official information
- Vpriv prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Velaglucerase alfa)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vpriv?
Vpriv (Velaglucerase alfa) is a specialist medicine made by Takeda Pharmaceuticals America, Inc., approved by the US FDA.
What are the ingredients of Vpriv?
Vpriv contains Velaglucerase Alfa (2.5 mg/mL).
Is Vpriv approved in Europe?
The same active substance is approved in the EU as Vpriv.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA